Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age

Justine Cormier, Catherine J ChuMassachusetts General Hospital, Department of Neurology, Programs in Child Neurology and Neurophysiology, Boston, MA, USAAbstract: Epilepsy is a common neurological disorder in the pediatric population, affecting up to one percent of children, and for which the mainst...

Full description

Bibliographic Details
Main Authors: Cormier J, Chu CJ
Format: Article
Language:English
Published: Dove Medical Press 2013-02-01
Series:Neuropsychiatric Disease and Treatment
Online Access:http://www.dovepress.com/safety-and-efficacy-of-levetiracetam-for-the-treatment-of-partial-onse-a12277
id doaj-65754c44c3b84d56ae57f5fe855b3988
record_format Article
spelling doaj-65754c44c3b84d56ae57f5fe855b39882020-11-24T21:03:49ZengDove Medical PressNeuropsychiatric Disease and Treatment1176-63281178-20212013-02-012013default295306Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of ageCormier JChu CJJustine Cormier, Catherine J ChuMassachusetts General Hospital, Department of Neurology, Programs in Child Neurology and Neurophysiology, Boston, MA, USAAbstract: Epilepsy is a common neurological disorder in the pediatric population, affecting up to one percent of children, and for which the mainstay of treatment is anticonvulsant medication. Despite the frequent use of anticonvulsant drugs, remarkably little is known about the safety and efficacy of most of these medications in the pediatric epilepsy population. Of 34 anticonvulsants currently approved for use by the US Food and Drug Administration (FDA), only 13 have been approved for use in children. Although infants and young children are disproportionately affected by epilepsy, there are currently only three anticonvulsant medications that have been specifically evaluated and approved for use in children younger than 2 years of age. In 2012, the FDA approved levetiracetam as an adjunctive treatment for partial onset seizures in infants and children from one month of age. Here we review the available data on levetiracetam in the pediatric epilepsy population. We first discuss the pharmacological profile of levetiracetam, including its mechanism of action, formulations and dosing, and pharmacokinetics in children. We then review the available efficacy, safety, and tolerability data in children from one month of age with partial onset seizures. We conclude that the current data leading to the approval of levetiracetam for use in infants and children with partial onset seizures is encouraging, although more work needs to be done before definitive conclusions can be drawn about the efficacy of levetiracetam across different pediatric age groups.Keywords: levetiracetam, anticonvulsant drug, partial seizures, pediatric epilepsyhttp://www.dovepress.com/safety-and-efficacy-of-levetiracetam-for-the-treatment-of-partial-onse-a12277
collection DOAJ
language English
format Article
sources DOAJ
author Cormier J
Chu CJ
spellingShingle Cormier J
Chu CJ
Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age
Neuropsychiatric Disease and Treatment
author_facet Cormier J
Chu CJ
author_sort Cormier J
title Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age
title_short Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age
title_full Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age
title_fullStr Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age
title_full_unstemmed Safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age
title_sort safety and efficacy of levetiracetam for the treatment of partial onset seizures in children from one month of age
publisher Dove Medical Press
series Neuropsychiatric Disease and Treatment
issn 1176-6328
1178-2021
publishDate 2013-02-01
description Justine Cormier, Catherine J ChuMassachusetts General Hospital, Department of Neurology, Programs in Child Neurology and Neurophysiology, Boston, MA, USAAbstract: Epilepsy is a common neurological disorder in the pediatric population, affecting up to one percent of children, and for which the mainstay of treatment is anticonvulsant medication. Despite the frequent use of anticonvulsant drugs, remarkably little is known about the safety and efficacy of most of these medications in the pediatric epilepsy population. Of 34 anticonvulsants currently approved for use by the US Food and Drug Administration (FDA), only 13 have been approved for use in children. Although infants and young children are disproportionately affected by epilepsy, there are currently only three anticonvulsant medications that have been specifically evaluated and approved for use in children younger than 2 years of age. In 2012, the FDA approved levetiracetam as an adjunctive treatment for partial onset seizures in infants and children from one month of age. Here we review the available data on levetiracetam in the pediatric epilepsy population. We first discuss the pharmacological profile of levetiracetam, including its mechanism of action, formulations and dosing, and pharmacokinetics in children. We then review the available efficacy, safety, and tolerability data in children from one month of age with partial onset seizures. We conclude that the current data leading to the approval of levetiracetam for use in infants and children with partial onset seizures is encouraging, although more work needs to be done before definitive conclusions can be drawn about the efficacy of levetiracetam across different pediatric age groups.Keywords: levetiracetam, anticonvulsant drug, partial seizures, pediatric epilepsy
url http://www.dovepress.com/safety-and-efficacy-of-levetiracetam-for-the-treatment-of-partial-onse-a12277
work_keys_str_mv AT cormierj safetyandefficacyoflevetiracetamforthetreatmentofpartialonsetseizuresinchildrenfromonemonthofage
AT chucj safetyandefficacyoflevetiracetamforthetreatmentofpartialonsetseizuresinchildrenfromonemonthofage
_version_ 1716772889757220864